蔡司 MyoCare 鏡片

蔡司 MyoCare 鏡片

MyoCare 配備蔡司創新科技，並以蔡司開發近視控制鏡片超過十年的經驗為基礎。

高效控制兒童近視
所有視角均提供良好視力
舒適視覺
全面紫外線防護

資料來源 - Ziess Hong Kong

蔡司 MyoCare 鏡片原理

蔡司 C.A.R.E. 技術（同心圓環鏡片結構）

其同心圓環特別結構由離焦度數區域和矯正度數區域交替組成，由鏡片表面中央分佈至周邊。這些微型結構可發送「停止訊號」，減緩眼軸增長。

蔡司ClearFocus設計

目的是阻止發送「生長訊號」，經優化的後表面可將周邊的遠視離焦減到最少。配戴者的度數矯正及預期的近視離焦在任何視覺方向維持不變。此技術有助蔡司MyoCare鏡片的有效性及配戴性。

資料來源 - Ziess Hong Kong

蔡司 MyoCare 產品組合的兩種設計

蔡司 MyoCare 鏡片

硬設計版本，具有較小的清晰區和更強的平均離焦度數，適合近視加深速度較快的年幼兒童。

7 mm Central zone

Add: +4.6D

Fill: 0.5

蔡司 MyoCare S
具有較大的中央清晰區和較柔和的平均離焦度數，更適合年齡較大的兒童和青少年，因為他們的近視加深速度較慢，並且需要更容易適應的鏡片。

9 mm Central zone

Add: +3.8D

Fill: 0.5

資料來源 - Ziess Hong Kong

蔡司 MyoCare 鏡片

蔡司 MyoCare 鏡片 – 效果

蔡司 MyoCare 設計可有效減緩近視加深，並且令眼睛成長狀況更接近正視眼生理成長曲線。

Reference

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology. 2016;123(5):1036–1042.
Chen M, Wu A, Zhang L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey. BMC Ophthalmol. 2018;18(1):159. doi: 10.1186/s12886-018-0829-8.
Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017; 9 5 ( 6 ):551- 5 6 6 . d o i: 10 .1111/ a o s .13 4 0 3.
Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE)
[Conference presentation abstract]. The Association for Research in Vision and OpthalmologyOphthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
EPR for ages 7-12 year old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13 years were considered, EPR for ZEISS MyoCare was 71%.
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Tianjin Eye Hospital Optometric Center, China, 2022, on 80 myopic children wearing ZEISS MyoCare Rx lenses, 80 myopic children wearing ZEISS MyoCare S Rx lenses and80 Myopic children wearing ZEISS Single Vision lenses. 12-months interim results presented at ARVO 2024.
Hong Kong Polytechnic University owns granted patents (including Chinese patent: CN103097940) on annular concentric lens for myopia control, which are licensed to Carl Zeiss. 自 2021 年起，卡爾‧蔡司開始與溫州醫科大學合作開發最新型的同心圓環鏡片結構技術，並用於 MyoCare 鏡片設計的眼鏡鏡片。